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OPIATE ANALOGS SELECTIVE FOR THE
8-OPOD RECEPTOR

SUMMARY OF THE INVENTION

Thus, in accordance with the present invention, there is
provided a compound having the formula:

The present application claims priority to co-pending U.S.
Provisional Application, Ser. No. 60/411,724 filed Sep. 18,

wherein

2002. The entire text of the above-referenced disclosure is

specifically incorporated herein by reference without dis
claimer.
10

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention relates generally to the fields of
pharmacology and more specifically to compounds and
treatments for pain management, immune disorders, and
drug addiction. More particularly, it provides a variety of
compositions and methods based on novel opiate analogs
having improved 6 opioid receptor selectivity.
2. Description of Related Art
Opioid analgesics are well known for their ability to
reduce the perception of pain without a loss of conscious
ness. Opium, the Source of natural opiates, contains a variety
of opiates including the familiar morphine and codeine.
Morphine possesses a variety of effects, among which are
increased tolerance to pain (analgesia). Somnolence, eupho
ria, antitussive activity, respiratory depression, constipation
and emesis. However, use of morphine is complicated by the
highly addictive nature of this narcotic. The scientific com
munity has focused a significant amount of time and effort
to find opioid analogs that exhibit the analgesic activity of
morphine and related opioids but possess improved oral
bioavailability and a diminished risk associated with addic
tion and other undesirable side effects.

At least three major types of opioid receptors (Ö, L, K) are
involved in the modulation of a variety of opioid effects. In
the field of opioid research, selective agonists for the
Ö-opioid receptor have shown promising therapeutic poten
tial as analgesics without the adverse side effects associated
with morphine and other opioid drugs which are selective
for the u-opioid receptor. The published literature contains
numerous references to the design and synthesis of novel
opioids, but only a few Successful attempts have been
reported in the development of non-peptide Ö-opioid recep
tor agonists. Several examples of non-peptide ligands have
been discovered either by modification of morphine-type
alkaloids or by random screening approaches (Portoghese et
al., 1993: Knapp et al., 1995; Knapp et al., 1996), but most
of these suffer from various problems such as poor selec
tivity and low efficacy in vivo. Liao et al. (1998) recently
reported the design, synthesis, and biological activity of
non-peptide compounds that target the Ö-opioid receptor.
Portoghese et al. (1998) also described modifications of their
“message' and “address' concept for designing receptor
specific opioid agonists and antagonists that confer selec
tivity for the 8-opioid receptor. Other reports of opioids
selective for the 8 receptor have also appeared (Ananthan et
al., 1998; Ananthan et al., 1999; Schiller et al., 1999;
Plobeck et al., 2000; Wei et al., 2000; WO 99/67203; WO
99/67206: U.S. Pat. No. 5,298,622; U.S. Pat. No. 4,816,586:

U.S. Pat. No. 5,457,208; and U.S. Pat. No. 6,359,111).
However, there remains a need for non-peptide opioid
compounds selective for the 8 receptor with improved oral
bioavailability and a diminished risk associated with addic
tion and other undesirable side effects.
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or wherein R and R can optionally comprise a ring system
selected from:

35
O

R is H or t-butyl; and
Rs is CH methylcyclopropane, a linear alkyl, a branched
alkyl, a substituted alkyl, or a substituted branched alkyl:
40

45

50

O

R is H, CH, a linear alkyl, a branched alkyl, a substituted
alkyl, or a substituted branched alkyl;
or a pharmaceutically acceptable salt thereof.
In particular embodiments, the invention encompasses a
pharmaceutical composition containing the compound of the
invention and a pharmaceutically acceptable carrier.
In a further embodiment, the invention encompasses a
method for treating disease mediated by the 6-opioid recep
tor which comprises administering an effective amount of a
compound of the formula:

55

60

wherein
65

R is O, NH, NR, S, SH, or SR; R is H. =O, t-butyl,
phenoxy, diphenylamine, thiophenyl, phenyl, or cyclo
hexane; R is phenyl or phenoxy;
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or wherein R and R comprise a ring system selected from:

6
-continued
5
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or wherein R and R comprise a ring system selected from:
2
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-continued

DESCRIPTION OF ILLUSTRATIVE
EMBODIMENTS

I. The Present Invention

10

or R is Hort-butyl, and Rs is CH methylcyclopropane, a
linear alkyl, a branched alkyl, a Substituted alkyl, or a
Substituted branched alkyl, or a pharmaceutically acceptable

15

salt thereof.

Also provided is a method for treating a patient compris
ing administering a therapeutically effective amount of a
compound of the present invention. A method for treating
disease mediated by the 6-opioid receptor comprising
administering an effective amount of a compound of the
present invention is also provided. The disease may com
prise of an immune disorder, transplant rejection, allergy,
inflammation, drug or alcohol abuse, diarrhea, cardiovascu
lar disease, or respiratory disease.
In yet another embodiment of the invention, methods are
provided for treatment of a disease comprising treating pain,
protecting brain cells, or decreasing gastric secretion.

25
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BRIEF DESCRIPTION OF THE DRAWINGS

The use of opiate analogues for treating pain, immune
disorders, or drug addiction can suffer from the problems of
poor selectivity, low efficacy in vivo, poor oral bioavailabil
ity, risks associated with addiction and other undesirable
side effects. There is great interest in the medical and
pharmacological community in the development of Ö-selec
tive opioids, such as naltrindole (NTI) and spiroindanyloxy
morphone (SIOM), that exhibit the analgesic activity of
morphine and related opioids while possessing improved
oral bioavailability and a diminished risked associated with
addiction and other undesirable side effects thus showing
promising therapeutic potential. The current methods used
to discover opiate analogues rely on the modification of the
morphine-type alkaloid structure or the random screening of
structures for activity. However, these approaches also suffer
from various drawbacks such as poor selectivity and low
efficacy in vivo.
Thus, the present invention provides novel methods
towards Screening for Ö-selective opioids. In addition syn
thetic routes for these novel 6-selective opioids are provided
along with methods for the use of the novel 8-selective
opioids. By virtue of their non-peptide chemical structure,
these novel 8-selective opioids should exhibit superior oral
tolerability and greater amenability to large-scale production
over peptide based opioids such as the enkephalins.
II. Opioid Receptors
Opioid drugs have various effects on perception of pain,
consciousness, motor control, mood, and autonomic func

The following drawings form part of the present specifi
cation and are included to further demonstrate certain

aspects of the present invention. The invention may be better
understood by reference to one or more of these drawings in
combination with the detailed description of specific
embodiments presented herein.
FIG. 1. Molecular structures of three opioids.
FIGS. 2A-2C. Plots of the CoMFA-predicted vs. experi
mentally observed binding affinities (pKi) for a series of
known opioids (FIG. 2A) 8 receptor data: (FIG. 2B) K
receptor data: (FIG. 2C) LL receptor data.
FIG. 3. Steric-electrostatic pharmacophore contour map
for the 8 opioid receptor based on the CoMFA model. The
structure of the opioid diprenorphin is shown for reference.
FIG. 4. Histograms comparing predicted binding affinities
of selected new candidates for the Ö, K, and L opioid
receptors: NTI analogues.
FIG. 5. Histograms comparing predicted binding affinities
of selected new candidates for the Ö, K, and L opioid
receptors: SIOM analogues.
FIG. 6. Calculated log P values for selected novel com
pounds vs. NTI.
FIGS. 7A-7B. Competitive analysis of the opoid ana
logue DST3-2. FIG. 7A Shows high delta binding affinity
(140 nM) of the DST3-2 analogue. The percent inhibition of
DST3-2 versus the delta receptor is shown using 1.64 nM of
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the reference compound H-Bremazocine. FIG. 7B Shows
good delta/mu selectivity (~10/1) of the DST3-2 analogue.
The percent specificity of DST3-2 versus the mu receptor is

shown using 1.64 nM of the reference compound H-Brema

Zocine.
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tion and can also induce physical dependence (Koob et al.,
1992). The endogenous opioid system plays an important
role in modulating endocrine, cardiovascular, respiratory,
gastrointestinal and immune functions (Olson et al., 1989).
Opioids exert their actions by binding to specific membrane
associated receptors located throughout the central and
peripheral nervous system (Pert and Snyder, 1973). The
endogenous ligands of these opioid receptors have been
identified as a family of more than 20 opioid peptides that
derive from the three precursor proteins proopiomelanocor
tin, proenkephalin, and prodynorphin (Hughes et al., 1975;
Akil, et al., 1984). Although the opioid peptides belong to a
class of molecules distinct from the opioid alkaloids, they
share the common structural features of a positive charge
juxtaposed with an aromatic ring which are required for
interaction with the receptor (Bradbury et al., 1976).
Results from pharmacological studies suggest that there
are numerous classes of opioid receptors, including those
designated ö, K, and u (Simon, 1991; Lutz and Pfister, 1992).
Biochemical characterization of opioid receptors from many
groups report a molecular mass of about 60,000 Da for all
three Subtypes, Suggesting that they could be related mol
ecules (Loh et al., 1990). However, the three classes differ in
their affinity for various opioid ligands and in their cellular
distribution, and thus the three different classes of opioid
receptors are believed to serve different physiological func
tions (Olson et al., 1989; Simon, 1991; Lutz and Pfister,
1992).
Among the three classes of opioid receptors, recent evi
dence Suggests that Ö-selective opioids could be potentially
useful as analgesics devoid of the numerous undesirable side
effects (e.g., respiratory depression, physical dependence
and gastrointestinal effects) associated with narcotics Such
as morphine (Blisky et al., 1995). It is known that morphine

US 7,164,021 B2
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interacts principally with the L receptors, and peripheral
administration of this opioid induces release of enkephalins
(Bertolucci et al., 1992). The 8 receptors bind with the
greatest affinity to enkephalins and have a more discrete
distribution in the brain than either L or K receptors, with
high concentrations in the basal ganglia and limbic regions.
Thus, enkephalins may mediate part of the physiological
response to morphine, presumably by interacting with Ö
receptors.

Moreover, selective antagonists of 8 receptors have been
shown to modulate the development of tolerance and depen
dence to Lagonists such as morphine (Abdelhamid et al.,
1991), to modulate the behavioral effects of drugs of abuse
such as cocaine (Reid et al., 1993), and to elicit favorable
immunomodulatory effects (House et al., 1995). The 8-se
lective opioid analogues thus represent extremely attractive
candidates for a broad range of novel pharmaceutical appli
cations including effective yet safe analgesics, immuno
modulatory agents for treating immune disorders, and new
treatments for drug addiction.
III. Opioids
The term opioid refers to all compounds in a generic sense
related to opium. The word opium is derived from opos, the
Greek word for juice, since the medicine was derived from
the juice of the opium poppy, papaver somniferum. Opiates
are drugs derived from opium, and include the natural
products morphine, codeine, thebaine, and many semi
synthetic congeners derived from them. Endogenous opioid
peptides (EOPs) are the naturally synthesized ligands for
opioid receptors. The term endorphin is used synonymously
with EOP, but also refers to a specific endogenous opioid,
B-endorphin. The term narcotic was derived from the Greek
word for stupor. At one time, it referred to any drug that
induced sleep, but then became particularly associated with
opioids.
Opioids such as heroin and morphine exert their effects by
mimicking naturally-occurring Substances, termed the
endogenous opioid peptides or endorphins. The endogenous
opioid system has been found to have both molecular and
biochemical complexity, as well as, widespread anatomy,
and diversity. These diverse functions subsume a house
keeping role in the body. They include the best-known
sensory role, prominent in inhibiting responses to painful
stimuli, a modulatory role in gastrointestinal, endocrine and
autonomic functions; an emotional role, evident in the

powerful rewarding and addicting properties of opioids; and
a cognitive role in the modulation of learning and memory.
Results from scientific studies have revealed the opioid
system to be a complex and Subtle system, with a great
diversity in endogenous ligands (over a dozen), yet with
only four major receptor types.
Of the four major receptor types, only three L, Ö, and K
have been extensively studied. The more recently discov
ered nociceptin/orphanin FQ receptor (N/OFO receptor; also
initially described as the opioid receptor-like 1 (ORL-1) or
“orphan' opioid receptor) has added a new dimension to the
study of opioids. Recently, a new nomenclature system has
been proposed to reflect the consideration of this receptor as
part of the opioid receptor family. It has been suggested by
the IUPHAR Nomenclature Committee that these receptors
be referred to as the OP (opioid peptide) receptor family and
individual receptors be called the u or MOP, 8 or DOP K or
KOP, and N/OFO or NOP receptors.
A. Effects of Clinically Used Opioids
Morphine and most other clinically used opioid agonists
exert their effects through L receptors. These drugs affect a
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wide range of physiological systems, including, analgesia,
mood, rewarding behavior, respiratory, cardiovascular, gas
trointestinal, and neuroendocrine function. Delta opioid
compounds are also potent analgesics in animals and
humans (Coombs et al., 1985). Many 8 agonists currently in
use are peptidergic and unable to cross the blood-brain
barrier, thus requiring intraspinal administration. The K
selective agonists produce analgesia that has been shown in
animals to be mediated primarily at spinal sites. Respiratory
depression and miosis may be less severe with K than with
Lagonists. Instead of euphoria, Lagonists produce dyspho
ric and psychotomimetic effects (Pfeiffer et al., 1986). In
neural circuitry mediating both reward and analgesia, LL and
K agonists have been shown to have antagonistic effects.
Mixed agonist-antagonist compounds were developed for
clinical use with the hope that they would have less addictive
potential and less respiratory depression. In practice, it has
turned out that for the same degree of analgesia, the same
intensity of side effects will be observed (APS 1999). A
"ceiling effect.'” limiting the amount of analgesia attainable,
is often seen with these compounds. Some drugs of this
class, such as pentazocine and nalorphine, can produce
severe psychotomimetic effects that are not naloxone revers
ible (which Suggest that they are not mediated through
classical opioid receptors). Also, these drugs can precipitate
withdrawal in opioid tolerant patients. For these reasons, the
clinical use of these compounds is relatively limited.
In human beings, morphine-like drugs produce analgesia,
drowsiness, changes in mood, and mental clouding. A sig
nificant feature of the analgesia is that it occurs without loss
of consciousness. When therapeutic doses of morphine are
given to patients with pain, they report that the pain is less
intense, less discomforting, or entirely gone; drowsiness
commonly occurs. In addition to relief of distress, some
patients experience euphoria.
When morphine in the same dose is given to a normal,
pain-free individual, the experience may be unpleasant.
Nausea is common, and vomiting also may occur. There may
be feelings of drowsiness, difficulty in mentation, apathy,
and lessened physical activity. As the dose is increased, the
Subjective, analgesic, and toxic effects, including respiratory
depression, become more pronounced. Morphine does not
have anticonvulsant activity and usually does not cause
slurred speech, emotional lability, or significant motor inco
ordination. The relief of pain by morphine-like opioids is
relatively selective, in that other sensory modalities are not
affected. Patients frequently report that the pain is still
present, but that they feel more comfortable. Continuous
dull pain is relieved more effectively than sharp intermittent
pain, but with sufficient amounts of opioid it is possible to
relieve even the severe pain associated with renal or biliary
colic.

55
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While opioids are primarily used clinically for their pain
modulatory properties, they produce a host of other effects.
This is not surprising in view of the wide distribution of
opioids and their receptors, both in the brain and in the
periphery. Opioids can produce muscular rigidity in human
beings; alter the equilibrium point of the hypothalamic
heat-regulatory mechanisms; inhibit the release of gonadot
ropin-releasing hormone (GnRH) and corticotropin-releas
ing factor (CRF) in the hypothalamus, cause constriction of
the pupil by an excitatory action on the parasympathetic
nerve innervating the pupil; produce convulsions in animals;
depress respiration, at least in part by virtue of a direct effect
on the brainstem respiratory centers; depress the cough
reflex, at least in part by a direct effect on a cough center in
the medulla, cause nausea and Vomiting by direct stimula
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tion of the chemoreceptor trigger Zone for emesis, in the area
postrema of the medulla, cause orthostatic hypotension and
fainting upon rising from a Supine position; decrease the
secretion of hydrochloric acid in the gastrointestinal tract;
diminishes biliary, pancreatic, and intestinal Secretions in the
Small intestine; diminishes or abolishes propulsive peristal
tic waves in the colon; inhibit gastrointestinal propulsive
activity in the bowels; increase the pressure in the common
bile duct, increase the tone and amplitude of contractions of
the ureter, and cause dilatation of cutaneous blood vessels in

the skin. Opioids have been shown to modulate immune
function both via direct, receptor-mediated effects on
immune cells and indirectly via centrally mediated neuronal
mechanisms (Gomez-Flores and Weber, 2000; Sharp and
Yaksh, 1997). The overall effects of opioids on immune
function appear to be suppressive, with increased suscepti
bility to infection and tumor spread observed in experimen

10

15

tal studies.

B. Morphine and Related Opioids
Because the laboratory synthesis of morphine is difficult,
the drug is still obtained from opium or extracted from
poppy Straw. Opium is obtained from the unripe seed
capsules of the poppy plant, Papaver somniferum. The
milkyjuice is dried and powdered to make powdered opium,
which contains a number of alkaloids. Only a few mor
phine, codeine, and papaverine—have clinical usefulness.

consciousness, motor control, mood, and autonomic func

25

These alkaloids can be divided into two distinct chemical

classes, phenanthrenes and benzylisoquinolines. The princi
pal phenanthrenes are morphine (10% of opium), codeine
(0.5%), and thebaine (0.2%). The principal benzylisoquino
lines are papaverine (1.0%), which is a smooth muscle
relaxant, and noscapine (6.0%).
Many semisynthetic derivatives are made by relatively
simple modifications of morphine or thebaine. Codeine is
methylmorphine, the methyl Substitution being on the phe
nolic hydroxyl group. Thebaine differs from morphine only
in that both hydroxyl groups are methylated and that the ring
has two double bonds. Thebaine has little analgesic action,
but is a precursor of several important 14-OH compounds,
Such as oxycodone and naloxone. Certain derivatives of
thebaine are more than 1000 times as potent as morphine
(e.g., etorphine). Diacetylmorphine, or heroin, is made from
morphine by acetylation at the 3 and 6 positions. Apomor
phine, which also can be prepared from morphine, is a potent
emetic and dopaminergic agonist. Hydromorphone, oxy
morphone, hydrocodone, and oxycodone also are made by
modifying the morphine molecule.
In addition to morphine, codeine, and the semisynthetic
derivatives of the natural opium alkaloids, a number of other
structurally distinct chemical classes of drugs have pharma
cological actions similar to those of morphine. Clinically
useful compounds include the morphinans, benzomorphans,
methadones, phenylpiperidines, and propionanilides.
Although the two-dimensional representations of these
chemically diverse compounds appear to be quite different,
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molecular models show certain common characteristics;

these are indicated by the heavy lines in the structure of
morphine shown above. Among the important properties of
the opioids that can be altered by structural modification are
their affinity for various species of opioid receptors, their
activity as agonists versus antagonists, their lipid solubility,
and their resistance to metabolic breakdown. For example,
blockade of the phenolic hydroxyl at position 3, as in
codeine and heroin, drastically reduces binding to LL recep
tors; these compounds are converted to the potent analgesics
morphine and 6-acetyl morphine, respectively, in vivo.

12
C. Side Effects of Opioids
Unfortunately, use of opioids can cause severe adverse
side effects including somnolence, euphoria, antitussive
activity, respiratory depression, emesis, changes in ther
moregulation, inhibition of gastrointestinal motility, muscle
rigidity, renal function, appetite, gastric secretion, learning
and memory, mental illness, epileptic seizures and other
neurological disorders, and the potential for physical depen
dence and abuse. The search for compounds exhibiting
minimal adverse side effects has led to the synthesis and
study of many opioid-like compounds.
The 6 receptors, along with the related K and LL receptors,
found on cells located throughout the central and peripheral
nervous system normally bind with opioid peptides (e.g.,
enkephalins) that the body produces. By binding to the
receptors, these peptides modulate endocrine, cardiovascu
lar respiratory, gastrointestinal, and immune functions.
Opioid narcotics are alkaloids, with molecular structures
quite distinct from opioid peptides. However, the narcotic
drugs and opioid peptides share common structural features
(known as pharmacophores) that enable the drugs to bind to
the opioid receptors. When they bind to these receptors, the
narcotics exert various effects on the perception of pain,
tion. They also induce physical dependence. However,
recently published studies (Schiller et al., 1999) demonstrate
that compounds (or combinations of compounds) that act in
concert as Lagonists and ö antagonists exhibit the potency
of opioids as pain killers yet without their negative side
effects such as physical addiction. This study, among others,
reveals that u agonists/ö antagonists are very attractive
targets as therapeutic agents. Similarly, opioid analogues
specific for the 8 receptor will potentially have much fewer
or less severe side effects than analogues targeted at other
opioid receptor types (Blisky et al., 1995).
The development of tolerance and physical dependence
with repeated use is another characteristic feature of all the
opioid drugs that may be lessened by using opioids having
superior 8 opioid receptor selectivity. Tolerance to the effect
of opioids or other drugs simply means that over time, the
drug loses its effectiveness at a specific dose level and an
increased dose is required to produce the same physiological
response. Dependence refers to a complex and poorly under
stood set of changes in the homeostasis of an organism that
is caused by a disturbance of the homeostatic set point of the
organism due to drug use cessation. This disturbance is often
called withdrawal. Addiction is a behavioral pattern char
acterized by compulsive use of a drug and overwhelming
involvement with its procurement and use. Tolerance and
dependence are physiological responses seen in all patients
and are not predictors of addiction. Cancer pain often
requires prolonged treatment with high doses of opioids,
leading to tolerance and dependence, but abuse in this
setting is very unusual (Foley, 1993). Opioids can be dis
continued in dependent patients once the need for analgesics
is gone without Subjecting them to withdrawal. Clinically,
the dose can be decreased by 10–20% every other day and
eventually stopped without signs and symptoms of with
drawal.
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It has been Suggested that highly selective opioid agonists
or antagonists might have therapeutic applications, and that
the potential side effects of Such analogues mediated through
other opioid receptors types can be minimized or eliminated.
(Martin, 1983). Among the three classes of opioid receptors
recent evidence Suggests that Ö-selective opioids could be
potentially useful as analgesics devoid of the numerous side
effects (e.g., respiratory depression, physical dependence
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and gastrointestinal effects) associated with narcotics Such
as morphine (Blisky et al., 1995). Moreover, selective
antagonists of 6 receptors have been shown to modulate the
development of tolerance and dependence to Lagonists Such
as morphine (Abdelhamid et al., 1991), to modulate the
behavioral effects of drugs of abuse such as cocaine (Reid et
al., 1993), and to elicit favorable immunomodulatory effects
(House et al., 1995). The 6-selective opioids thus represent
extremely attractive candidates for a broad range of novel
pharmaceutical applications including powerful yet safe
analgesics, immunomodulatory agents for treating immune
disorders, and new treatments for drug addiction. The
present invention provides novel opioid analogues and
methods for predicting and producing these novel opioid
analogues that target the 8 opioid receptor.
IV. Non-Peptide Opioid Analogues
The basic design strategy for non-peptide opioid ana
logues is based on the “message-address' concept developed
to rationalize the separate pharmacophoric features of opio
ids that confer affinity versus selectivity (Takemori and
Portoghese, 1992). The “message” represents those struc
tural features common to all opioids that are recognized
similarly by the three types of receptors (Ö, K, u). The
“address' represents those specific structural features that
confer high selectivity for a particular (e.g., 8) opioid

10

15

25

NOPs described herein include immunomodulators for

autoimmune diseases Such as arthritis, skin grafts, organ
transplants, collagen diseases, allergies, anti-tumor agents,
anti-viral agents, and Surgical needs. The treatment of con
ditions such as diarrhea, depression, urinary inconsistency,
mental illness, cough, lung edema, gastro-intestinal disor
ders and spinal injury is also considered. The NPOs may be
used for the treatment of drug addiction, where the drug is
an opioid or another Substance Such as alcohol or nicotine.
“Disease' or “condition’ for which compounds of the
present invention are applicable include, but are not limited
to, for example, the treatment of inflammation in a Subject,
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and for treatment of other inflammation-associated disor

ders, such as, an analgesic in the treatment of pain and
headaches, or as an antipyretic for the treatment of fever.
Compounds of the invention may be useful to treat arthritis,
including but not limited to rheumatoid arthritis, spondy
loarthopathies, gouty arthritis, osteoarthritis, systemic lupus
erythematosus, and juvenile arthritis. Compounds of the
invention may be useful in the treatment of asthma, bron
chitis, menstrual cramps, tendinitis, bursitis, and skin related
conditions such as psoriasis, eczema, burns and dermatitis.
Compounds of the invention also may be useful to treat
gastrointestinal conditions such as inflammatory bowel dis
ease, Crohn's disease, gastritis, irritable bowel syndrome,
and ulcerative colitis, and for the prevention or treatment of
cancer, such as colorectal cancer. Compounds of the inven
tion may be useful in treating inflammation in Such diseases
as vascular diseases, migraine headaches, periarteritis
nodosa, thyroiditis, aplastic anemia, Hodgkins disease, scle
rodoma, rheumatic fever, type I diabetes, myasthenia gravis,

the treatment of arthritis, with the additional benefit of

having significantly less harmful side effects, allergic rhini
tis, respiratory distress syndrome, endotoxin shock and
trauma. Compounds of the invention may be useful in
interdicting or modifying the effects of other biologically
active compounds such as narcotic addiction. Compounds of
the invention may be useful for treating diseases or condi
tions other than ones associated with receptors, for example,
blocking, inhibiting, or promoting, metabolic pathways or
enzyme function, and selectively interacting with genetic
material.

receptor.

V. Uses for Non-Peptide Opioid (NPO) Analogues
The Non-Peptide Opioids (NPOs) of the current invention
may be used for analgesis as well as a variety of other
therapies. When used as an analgesic, the condition may be
chronic pain, acute pain, pain caused by cancer, arthritis,
migraines, etc. Other therapies that may be treated with the
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multiple Sclerosis, sarcoidosis, nephrotic syndrome, Beh
cet’s syndrome, polymyositis, gingivitis, hyperSensitivity,
Swelling occurring after injury, myocardial ischemia, and
related diseases. The compounds may also be useful in the
treatment of ophthalmic diseases, such as retinitis, retino
pathies, conjunctivitis, uveitis, ocular photophobia, and of
acute injury to the eye tissue. The compounds may also be
useful in the treatment of pulmonary inflammation, such as
that associated with viral infections and cystic fibrosis. The
compounds may also be useful for the treatment of certain
central nervous system disorders such as cortical dementias
including Alzheimer's disease. The compounds of the inven
tion may be useful as anti-inflammatory agents, such as for
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VI. Bioavailability of Opioid Analogues
The bioavailability and activity of the NPOs of the
current invention for the 6 receptor can be screened before
use to determine their effectiveness. For example, a radio
ligand binding assay may be used to measure the bioavail
ability or activity of the NPOs of the current invention (U.S.
Pat. No. 5,922,887). Bioavailability, which includes the
absorption, distribution, metabolism, excretion (ADME)
and toxicity of a compound, is often difficult to predict based
on theoretical-computational methods. For true drug candi
dates, experimental tests are performed in vivo on animal
models and the results are extrapolated to humans. Methods
for determining bioavailibility can be found in a number of
reference books covering the topic (Dressman, 2000; Hard
man, 2001; or Saltzman, 2001). For screening purposes, one
of ordinary skill can use log P to estimate the hydrophobic
hydrophilic balance and water solubility of a compound. The
lopP value is determined experimentally or estimated com
putationally, where “P” refers to the “partitioning of a
compound between an organic phase (usually n-octanol) and
an aqueous phase (water). HPLC and other modern experi
mental techniques can be used to determine bioavailability
(Kaliszan, et al. 2001). Another technique used to determine
bioavailibility is the traditional “shaker procedure in which
a compound is introduced into a separatory funnel contain
ing equal amounts of n-octanol and water. After shaking the
flask, containing the compound of the current invention, to
achieve equilibrium, the amounts (concentrations) of com
pound in the organic phase and aqueous phase are measured.
Log P is then calculated as the logarithm (base 10) of the
ratio of the amount (or concentration) of compound in the
organic phase relative to that in the aqueous phase (log
P-logorganic/water). Values schemes have been devel
oped to estimate Log P values computationally. A more
common value scheme method. Such as C log P. estimates
the Log P value of a compound by adding “C log P
contributions' (stored in a database) from various fragments
or components of the compound. Other “adjustment terms
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can be added to correct for various inaccuracies using the C
log P method (see on the World WideWeb BioByte website).
VII. Chemistry
A. Key Structural Groups
The “message-address’ concept referred to above is illus
trated in Table 1 using the 6-selective antagonist NTI and the
6-selective agonist SIOM as examples. The high selectivity
of NTI and SIOM for the 8-receptor has been attributed to
their hydrophobic benzene moiety attached to the morphinan
nucleus. Conformational constraint of this address group is
a prerequisite for enhanced selectivity towards the 8 opioid
receptor. This benzene moiety is conformationally con
strained by the pyrrolo scaffold in NTI and by the spirocy
clopentano scaffold in SIOM. Selectivity for the 8 receptor
is enhanced by incorporating a hydrophobic moiety at the
morphinan ring position.

16
Scheme 1

General Synthetic Pathway of
Oxymorphone and Naltrexone
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Furthermore, naltrexone can be derivatized by addition of
various substituents. One compound, OP-44a and OP-44b.
has been found to be a particularly useful analogue having
a predicted 8 receptor activity of 11.19 (Scheme 5).

50

Spiroindanyloxymorphone (SIOM)

55

Table 1: Illustration of 8-selective address in two opiods:
NTI, a 6-selective antagonist and SIOM, a 6-selective ago
nist.

B. Synthetic Routes
Generally, the NPOs of the current invention can be
synthesized from known opioids by methods known in the
art. One starting material, naltrexone, could be used to
synthesize a number of compounds of the current invention.
Naltrexone or oxymorphone can be synthesized from
noroxymorphone as shown in Scheme 1.

60
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R2 = H, alkyl, alkoxy, amine
nitro, halogen etc.
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The derivatization of the naltrexone synthesized by the
route shown in Scheme 1, is exemplified in Scheme 2, where
OP-39, OP-41 and OP-44 are each synthesized using dif

18
Further modifications of the NPOs can be accomplished
by reacting the intermediate NPO with other reactants to
form a variety of substituted or unsubstituted heterocyclic
rings. Scheme 3 depicts some possible modifications of
OP-44 with variations at the ring labled A. These synthetic
schemes can be accomplished by general synthetic methods

ferent functionalities for R.

known in the art.
Scheme 2

General Synthetic Scheme of Naltrindole Derivatives
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Scheme 3
Possible Modification of OP-44 Derivatives
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30 A: All
heterocycle rings
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Other possible synthetic pathways for NPO derivatives
structurally similar to OP-26 is shown in Scheme 4 where
bromination and addition steps allow for the addition of
various functionalities to the NPO.

Scheme 4

Possible Synthetic Pathway of OP-26 Derivatives
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NPO analogues similar to OP-44a and OP-44b can be
synthesized by similar methods or as described in Liao et al.
(1998); Stevens et al. (2000) and Connet al. (1990). Scheme

5 summarizes possible synthetic pathways of OP-44a and
OP-44b derivatives.

Scheme 5

Summarized Synthetic Pathway of OP-44 derivatives
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NPO analogues similar to OP-26 can be synthesized by
methods such as those described in Scheme 6.
Scheme 6

Possible Synthetic Pathway of OP-44
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22
reoisomeric form, or mixture thereof, of a compound of the
invention, which possesses the useful properties described
herein, it being well known in the art how to prepare
optically active forms (for example, by resolution of the
racemic form by recrystallization techniques, by synthesis
from optically-active starting materials, by chiral synthesis,
or by chromatographic separation using a chiral stationary
phase). It is also well known in the art, and for example, as
illustrated herein below how to determine opioid receptor
activity, for example, 6, LL or K, or related receptor activity
using the standard tests described herein, or using other
similar tests.
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The stereochemistry of the NPOs is important in that
changing the Stereocenters affects the activity of the com
pound (Ohkawa et al., 1998). The effect of stereochemistry
for the NPO OP-26 and the Saturated derivatives on the

O

activity of the 8 receptor was studied. The molecules studied
include:
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NPOS with hydrazine-HCl salts can be synthesized as
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Scheme 7

General Synthetic Pathway of Hydrazine-HCl Salts
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The predicted activity for 6. L and K receptors as well as
the C log P were determined and are shown in Table 2.

N
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SnCl2.HC HO

N

N

Naltrexone and other starting materials can be prepared
and purified by synthetic methods which are well known in
the art (Ananthan et al., 1999).
A. Stereochemistry
It will be appreciated by those skilled in the art that
compounds of the invention having a chiral center may exist
in and be isolated in optically active and racemic forms.
Some compounds may exhibit polymorphism. It is to be
understood that the present invention encompasses any
racemic, optically-active, polymorphic, tautomeric, or Ste

R2 = H, p-NO or p-F
Strong electron withdrawing group

55

TABLE 2
Compound
OP-26
60 OP-26 R
OP-26 S

65

8 receptor

I receptor

K receptor

ClogP

1O.S1
9.1O
10.36

7.45
6.74
6.53

6.92
6.07
6.49

1.OO
O.90
O.90

As shown in Table 2, the greatest activity for the 8
receptor is seen with OP-26, with the R isomer having the
lowest activity. The activity towards the L and K receptors is
also greatly affected by the stereochemistry. Similarly, with
compounds OP-3 OP-4, and OP-5, which are all isomers of
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each other, the greatest predicted activity towards the 8
receptor is for the OP-4 which has one R and three S
StereocenterS.

B. Chemical Definitions

The term “alkyl refers to the saturated aliphatic groups,
including straight-chain alkyl groups, branched-chain alkyl
groups, cycloalkyl (alicyclic) groups, alkyl Substituted
cycloalkyl groups, and cycloalkyl Substituted alkyl groups.
The alkyls of the current invention are preferably from
between 1 and 20 carbons in length.
The term “linear alkyl refers to alkyls which have a
straight chain, Such as n-butane, n-pentane, n-hexane etc.
The term “branched alkyl refers to alkyls with one or
more branch off of the hydrocarbon backbone. Such moi
eties can include, for example, t-butyl, isopropyl. Sec-butyl,

10

described above.
15

etc.

The term “ring system” refers to a composition or part of
a composition having two or more connected cyclic moi
eties. The rings may be comprised of carbon or a combina
tion of carbon, nitrogen, oxygen or Sulfur and will have
between three and eight members in each ring. The rings
may be saturated or unsaturated and may be substituted or
unsubstituted.

The term “substituted alkyl refers to alkyl moieties
having moieties replacing a hydrogen on one or more
carbons of the hydrocarbon backbone. Such moieties can
include, for example, halogen, hydroxyl, alkylcarbonyloxy,
arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy,
carboxylate, alkylcarbonyl, alkoxycarbonyl, aminocarbonyl,
alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phos
phinato, cyano, amino (including alkylamino, dialkylamino,
arylamino, diarylamino, and alkylarylamino), acylamino
(including alkylcarbonylamino, arylcarbonylamino, car
bamoyl and ureido), amidino, imino, Sulfhydryl, alkylthio.
arylthio, thiocarboxylate, Sulfate, Sulfonato, Sulfamoyl, Sul
fonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl,
aralkyl, or an aromatic or heteroaromatic moiety. It will be
understood by those skilled in the art that the moieties
substituted on the hydrocarbon chain can themselves be
substituted, if appropriate. Cycloalkyls can be further sub
stituted, e.g., with the moieties described above. An
“aralkyl moiety is an alkyl substituted with an aryl (e.g.,
phenylmethyl (benzyl)).
The term “substituted branched alkyl refers to an alkyl
that is both substituted and branched.

As used herein, the term “organic moiety' is intended to
include carbon based functional groups such as alkyl, alky
lamino, alkoxy, aryl, aralkyl, aryloxy, alkylthio, and alkyl
carboxyl.
As used herein, the term “inorganic moiety' is intended to
include non carbon-based groups or elements such as hydro
gen, halo, amino, nitro, thiol, and hydroxyl.
As used herein, the term “halosubstituted alkyl moieties”
is intended to include alkyl moieties which have halogen
moieties in the place of at least one hydrogen.
As used herein, the term "nitro” means - NO; the term
"halogen designates —F. —Cl. —Br or —I; the term
“thiol means —SH; and the term “hydroxyl means —OH.
Thus, the term “alkylamino” as used herein means an alkyl
group, as defined above, having an amino group attached
thereto. The term “alkylthio’ refers to an alkyl group, as
defined above, having a Sulfhydryl group attached thereto.
The term “alkylcarboxyl as used herein means an alkyl
group, as defined above, having a carboxyl group attached
thereto.

The term 'aromatic group' is intended to include unsat
urated cyclic hydrocarbons containing one or more rings.
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Aromatic groups include 5- and 6-membered single-ring
groups which may include from Zero to four heteroatoms,
for example, benzene, pyrrole, furan, thiophene, imidazole,
oxazole, thiazole, triazole, pyrazole, pyridine, pyrazine,
pyridazine and pyrimidine, and the like. The aromatic ring
may be substituted at one or more ring positions with, for
example, a halogen, a lower alkyl, a lower alkenyl, a lower
alkoxy, a lower alkylthio, a lower alkylamino, a lower
alkylamine, a lower alkylcarbonyl, a nitro, a hydroxyl,
—CF, —CN, or the like.
The term “alkoxy’, as used herein, refers to a moiety
having the structure —O-alkyl, in which the alkyl moiety is

25

The term “aryl as used herein includes 5- and 6-mem
bered single-ring aromatic groups that may include from
Zero to four heteroatoms, for example, unsubstituted or
Substituted benzene, pyrrole, furan, thiophene, imidazole,
oxazole, thiazole, triazole, pyrazole, pyridine, pyrazine,
pyridazine and pyrimidine, and the like. Aryl groups also
include polycyclic fused aromatic groups such as naphthyl,
quinolyl, indolyl, and the like. The aromatic ring can be
Substituted at one or more ring positions with Such moieties,
e.g., as described above for alkyl groups. Preferred aryl
groups include unsubstituted and Substituted phenyl groups.
The term “aryloxy’, as used herein, refers to a group
having the structure —O-aryl, in which the aryl moiety is as
defined above.
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The term “amino,” as used herein, refers to NH or an
unsubstituted or substituted moiety of the formula—NRR,
in which R, and R, are each independently, hydrogen, alkyl,
aryl, or heterocyclyl, or R, and R, taken together with the
nitrogen atom to which they are attached, form a cyclic
moiety having from 3 to 8 atoms in the ring. Thus, the term
“amino' is intended to include cyclic amino moieties such as
piperidinyl or pyrrolidinyl groups, unless otherwise stated.
An "amino-Substituted amino group' refers to an amino
group in which at least one of R and R is further
Substituted with an amino group.
As used herein the term "agonist” refers to a signaling
molecule (hormone, neurotransmitter of synthetic drug)
which binds to a receptor, inducing a conformational change
which produces a response Such as contraction, relaxation,
secretion, change in enzyme activity, etc. The term “antago
nist” refers to a drug which attenuates the effect of an
agonist. Antagonist may be divided either on the basis of
being Surmountable or insurmountable (synononymous with
unsurmountable), or on the basis of being competitive, or
non-competitive.
As used herein the specification, “a” or “an may mean
one or more. As used herein in the claim(s), when used in
conjunction with the word “comprising, the words “a” or
'an' may mean one or more than one. As used herein
"another may mean at least a second or more. As used
herein, the term “about” means within 25% of the stated

value, or more preferentially within 15% of the value.
VIII. Pharmaceutical Preparations
Pharmaceutical compositions of the present invention
comprise an effective amount of one or more opiate ana
logues disclosed herein and/or an additional agent dissolved
or dispersed in a pharmaceutically acceptable carrier. The
phrases “pharmaceutical or pharmacologically acceptable'
refers to molecular entities and compositions that do not
produce an adverse, allergic or other untoward reaction
when administered to an animal. Such as, for example, a
human. The preparation of a pharmaceutical composition
that contains at least one opiate analogue or additional active
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ingredient will be known to those of skill in the art in light
of the present disclosure, as exemplified by Remington's
Pharmaceutical Sciences, 18th Ed. Mack Printing Company,
1990, incorporated herein by reference. Moreover, for ani
mal (e.g., human) administration, it will be understood that
preparations should meet Sterility, pyrogenicity, general
safety and purity standards as required by FDA Office of
Biological Standards.
As used herein, “pharmaceutically acceptable carrier'
includes any and all solvents, dispersion media, antioxi
dants, salts, coatings, Surfactants, preservatives (e.g., methyl
or propyl p-hydroxybenzoate, Sorbic acid, antibacterial
agents, antifungal agents), isotonic agents, Solution retarding
agents (e.g., paraffin), absorbents (e.g., kaolin clay, bentonite
clay), drug stabilizers (e.g., sodium lauryl Sulphate), gels,
binders (e.g., syrup, acacia, gelatin, Sorbitol, tragacanth,
polyvinylpyrrolidinone, carboxy-methyl-cellulose, algi
nates), excipients (e.g., lactose, milk Sugar, polyethylene
glycol), disintegration agents (e.g., agar-agar, starch, lactose,
calcium phosphate, calcium carbonate, alginic acid, Sorbitol,
glycine), wetting agents (e.g., cetyl alcohol, glycerol
monostearate), lubricants, absorption accelerators (e.g., qua
ternary ammonium salts), editable oils (e.g., almond oil,
coconut oil, oily esters or propylene glycol), Sweetening
agents, flavoring agents, coloring agents, fillers, (e.g., starch,
lactose, Sucrose, glucose, mannitol), tabletting lubricants
(e.g., magnesium Stearate, starch, glucose, lactose, rice
flower, chalk), carriers for inhalation (e.g., hydrocarbon
propellants), buffering agents, or Such like materials and
combinations thereof, as would be known to one of ordinary
skill in the art (see, for example, Remington’s Pharmaceu
tical Sciences, 1990, incorporated herein by reference).
Except insofar as any conventional carrier is incompatible
with the active ingredient, its use in the therapeutic or
pharmaceutical compositions is contemplated.
In any case, the composition may comprise various anti
oxidants to retard oxidation of one or more component.
Examples of antioxidants includes ascorbic acid, cysteine
hydrochloride, sodium sulfite, sodium bisulfite, sodium met
abisulfite, ascorbyl palmitate, butylated hydroxytoluene,
butylated hydroxyanisole, lecithin, propyl gallate, and C-to
copherol. Additionally, the prevention of the action of
microorganisms can be brought about by preservatives Such
as various antibacterial and antifungal agents, including but
not limited to parabens (e.g., methylparabens, propylpara
bens), chlorobutanol, phenol, Sorbic acid, thimerosal or
combinations thereof).
The opiate analogue may be formulated into a composi
tion in a free base, neutral or salt form. Pharmaceutically
acceptable salts, include the acid addition salts, e.g., those
formed with the free amino groups of a proteinaceous
composition, or which are formed with inorganic acids Such
as for example, hydrochloric, hydrobromic, or phosphoric
acids; or such organic acids as acetic, oxalic, tartaric,
benzoic, lactic, phosphorific, citric, maleaic, fumaric, suc
cinic, tartaric, napsylic, clavulanic, Stearic, or mandelic acid.
Salts formed with the free carboxyl groups can also be
derived from inorganic bases such as for example, Sodium,
potassium, ammonium, calcium magnesium or ferric
hydroxides; or Such organic bases as isopropylamine, trim
ethylamine, histidine or procaine.
In embodiments where the composition is in a liquid
form, a carrier can be a solvent or dispersion medium
comprising but not limited to, water, ethanol, polyol (e.g.,
glycerol, propylene glycol, liquid polyethylene glycol, etc.),
lipids (e.g., triglycerides, vegetable oils, liposomes) and
combinations thereof. The proper fluidity can be maintained,

5
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for example, by the use of a coating, such as lecithin; by the
maintenance of the required particle size by dispersion in
carriers such as, for example liquid polyol or lipids; by the
use of Surfactants such as, for example hydroxypropylcel
lulose; or combinations thereof Such methods. In many
cases, it will be preferable to include isotonic agents, such
as, for example, Sugars, sodium chloride or combinations
thereof.

10
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The opiate analogue may also comprise different types of
carriers depending on whether it is to be administered in
solid or liquid form, and whether it need to be sterile for such
routes of administration as injection. The present invention
can be administered orally, intradermally, Subcutaneously,
topically, by injection, infusion, continuous infusion, local
ized perfusion, bathing target cells directly, via a catheter,
via a lavage, in cremes, in lipid compositions (e.g., lipo
Somes), or by other method or any combination of the
foregoing as would be known to one of ordinary skill in the
art (see, for example, Remington’s Pharmaceutical Sciences,
1990, incorporated herein by reference).
The opiate analogue when administered orally may be in
the form of tablets, capsules, Sachets, vials, powders, gran
ules, lozenges, reconstitutable powders, liquid preparations.
The NPO may be admistered via transdermal delivery using
a skin-patch formulation. The NPO may be dispersed in a
pressure sensitive adhesive which adheres to the skin such
that it can diffuse through the skin for delivery to the patient.
Transdermal adhesives such as natural rubber or silicone are
known in the art.
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Sterile injectable solutions are prepared by incorporating
the active compounds in the required amount in the appro
priate solvent with various of the other ingredients enumer
ated above, as required, followed by filtered sterilization.
Generally, dispersions are prepared by incorporating the
various sterilized active ingredients into a sterile vehicle
which contains the basic dispersion medium and/or the other
ingredients. In the case of sterile powders for the preparation
of sterile injectable solutions, Suspensions or emulsion, the
preferred methods of preparation are vacuum-drying or
freeze-drying techniques which yield a powder of the active
ingredient plus any additional desired ingredient from a
previously sterile-filtered liquid medium thereof. The liquid
medium should be suitably buffered if necessary and the
liquid diluent first rendered isotonic prior to injection with
Sufficient saline or glucose. The preparation of highly con
centrated compositions for direct injection is also contem
plated, where the use of DMSO as a solvent is envisioned to
result in extremely rapid penetration, delivering high con
centrations of the active agents to a small area.
The actual dosage amount of a composition of the present
invention administered to a patient can be determined by
physical and physiological factors such as the severity of the
pain, body weight, gender, severity of condition, the type of
disease being treated, previous or concurrent therapeutic
interventions, idiopathy of the patient, time of the adminis
tration, rate of excretion of the particular compound, and on
the route of administration. The practitioner responsible for
administration will, in any event, determine the concentra
tion of active ingredient(s) in a composition and appropriate
dose(s) for the individual subject. The dosage will also
depend upon the bioavailability and activity of the particular
NPO.

65

In certain embodiments, pharmaceutical compositions
may comprise, for example, at least about 0.1% of an active
compound. In other embodiments, the active compound may
comprise between about 2% to about 75% of the weight of
the unit, or between about 25% to about 60%, for example,
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and any range derivable therein. In other non-limiting precede or follow the other agent treatment by intervals
examples, a dose may also comprise from about 1 micro ranging from minutes to weeks. In other aspects, one or
gram/kg/body weight, about 5 microgram/kg/body weight, more agents may be administered within from about 1
about 10 microgram/kg/body weight, about 50 microgram/ minute, about 5 minutes, about 10 minutes, about 20 min
kg/body weight, about 100 microgram/kg/body weight, 5 utes, about 30 minutes, about 45 minutes, about 60 minutes,
about 200 microgram/kg/body weight, about 350 micro about 2 hours, about 3 hours, about 4 hours, about 5 hours,
gram/kg/body weight, about 500 microgram/kg/body about 6 hours, about 7 hours, about 8 hours, about 9 hours,
weight, about 1 milligram/kg/body weight, about 5 milli about 10 hours, about 11 hours, about 12 hours, about 13
gram/kg/body weight, about 10 milligram/kg/body weight, hours, about 14 hours, about 15 hours, about 16 hours, about
about 50 milligram/kg/body weight, about 100 milligram/ 10 17 hours, about 18 hours, about 19 hours, about 20 hours,
kg/body weight, about 200 milligram/kg/body weight, about about 21 hours, about 22 hours, about 23 hours, about 24
350 milligram/kg/body weight, about 500 milligram/kg/ hours, about 25 hours, about 26 hours, about 27 hours, about
body weight, to about 1000 mg/kg/body weight or more per 28 hours, about 29 hours, about 30 hours, about 31 hours,
administration, and any range derivable therein. In non about 32 hours, about 33 hours, about 34 hours, about 35
limiting examples of a derivable range from the numbers 15 hours, about 36 hours, about 37 hours, about 38 hours, about
listed herein, a range of about 5 mg/kg/body weight to about 39 hours, about 40 hours, about 41 hours, about 42 hours,
100 mg/kg/body weight, about 5 microgram/kg/body weight about 43 hours, about 44 hours, about 45 hours, about 46
to about 500 milligram/kg/body weight, etc., can be admin hours, about 47 hours, to about 48 hours or more prior to
and/or after administering the opiate analogue. In certain
istered, based on the numbers described above.
The composition must be stable under the conditions of 20 other embodiments, an agent may be administered within
manufacture and storage, and preserved against the contami from about 1 day, about 2 days, about 3 days, about 4 days,
nating action of microorganisms, such as bacteria and fungi. about 5 days, about 6 days, about 7 days, about 8 days, about
It will be appreciated that endotoxin contamination should 9 days, about 10 days, about 11 days, about 12 days, about
13 days, about 14 days, about 15 days, about 16 days, about
be kept minimally at a safe level, for example, less that 0.5
25 17 days, about 18 days, about 19 days, about 20, to about 21
ng/mg protein.
In particular embodiments, prolonged absorption of an days prior to and/or after administering the opiate analogue.
injectable composition can be brought about by the use in In some situations, it may be desirable to extend the time
the compositions of agents delaying absorption, such as, for period for treatment significantly, however, where several
example, aluminum monostearate, gelatin or combinations weeks (e.g., about 1, about 2, about 3, about 4, about 5, about
30 6, about 7 or about 8 weeks or more) lapse between the
thereof.
Administration of opioids in the epidural or intrathecal respective administrations.
Various combinations may be employed, where the opiate
space provides more direct access to the first pain-process
ing synapse in the dorsal horn of the spinal cord. This analogue is “A” and the secondary agent is “B”:
A/B/AB/A/B B/BFAA/A/B A/B/B B/A/A A/B/B/B B/Af
permits the use of doses substantially lower than those
BFB BFB/BFA BABFA/B AFAFBFB A/B/AFB A/B/BFA
required for oral or parenteral administration, and may be 35
B/B/A/A B/A/B/A B/A/A/B AIA/A/B B/AIA/A A/B/
used in the current invention since systemic side effects are
A/A A/A/B/A
thus decreased. However, epidural opioids have their own
Administration of the therapeutic expression constructs of
dose-dependent side effects, such as itching, nausea, vom
iting, respiratory depression, and urinary retention. As a the present invention to a patient will follow general proto
consequence, after intraspinal administration, delayed res- 0 cols for the administration of opiods, taking into account the
piratory depression can be observed. While the risk of toxicity, if any, of the vector. It is expected that the treatment
delayed respiratory depression is reduced with more lipo cycles would be repeated as necessary. It also is contem
philic opioids it is not removed. Extreme vigilance and plated that various standard therapies, as well as Surgical
appropriate monitoring is required for all patients receiving intervention, may be applied in combination with the
intraspinal narcotics. Nausea and Vomiting are also more 45 described opiod therapy.
Opioid analgesics that can be used in conjugation with the
prominent symptoms with intraspinal opioids. However,
Supraspinal analgesic centers can also be stimulated, possi opiate analogue of the current invention include, but are not
limited to morphine, morphine Sulphate, tramadol, codeine,
bly leading to synergistic analgesic effects.
Analogous to the relationship between systemic opioids levorphanol, meperidine and congeners such as diphenoxy
and NSAIDS, intraspinal narcotics are often combined with 50 late and loperaminde, Sufentanil citrate and congeners such
alfentanil and remifentanil, methadone and congeners,
local anesthetics. This permits the use of lower concentra as
levomethadyl
acetate (LAAM), propoxyphene, butorphanol,
tions of both agents, minimizing local anesthetic complica
tions of motor blockade and the opioid induced complica eptazocine, fentanyl, fentanyl citrate, flupirtine, hydromor
tions listed above. Epidural administration of opioids have 55 phone and oxycodone. Other opioid compounds that may be
become popular in the management of postoperative pain, used include, but are not limited to pentazocine, nalbuphine,
and for providing analgesia for labor and delivery. Lower butorphanol, buprenorphine, meptazinol, dezocine, nalor
systemic opioid levels are achieved with epidural opioids, phine, levallorphan and nalmefene, morphine-6-glucu
morphine (DepoMorphine, AERX Pain Management
leading to less placental transfer and less potential for ronide,
respiratory depression of the newborn (Schnider and 60 System, Multipor technology), morphine Sulphate, pulmo
Levinson 1987). Intrathecal (“spinal anesthesia) adminis nary-delivered morphine Sulphate, and other morphine-like
tration of opioids as a single bolus is also popular for acute compounds including conorfone, propiram fumarate, Vari
ous strength opioid analgesics using OROS technology,
pain management.
various strength analgesics using Geomatrix technology,
IX. Combination Therapy
fentanyl, AERX Pain Management System, buprenorphine,
It is an aspect of this invention that the opiate analogue 65 asimadoline, TRK-820, LEF (BCH-3963), loperamide, oxy
can be used in combination with another agent, such as an codone and oxycodone combinations (i.e. oxycodone+ibu
opioid or other theraputic agent. The opiate analogue may profen or oxycodone-paracetamol), DPI-3290, ADL-10
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01.01, Xorphanol, TSN-09, and a combination of NMDA
antagonist and an opioid compound, (i.e. dextromethor
phan+hydrocodone, dextromethorphan+morphine and dex
tromethorphan+oxycodone+paracetamol) ('Advances in
Pain Management,” Scrip Reports, February 2000).
X. EXAMPLES

The following examples are included to demonstrate
preferred embodiments of the invention. It should be appre
ciated by those of skill in the art that the techniques
disclosed in the examples which follow represent techniques
discovered by the inventor to function well in the practice of

10

the invention, and thus can be considered to constitute

preferred modes for its practice. However, those of skill in
the art should, in light of the present disclosure, appreciate
that many changes can be made in the specific embodiments

15

statistical self-consistency (r-0.90) and internal predictive
ability (ref>0.60). The regression equations corresponding

which are disclosed and still obtain a like or similar result

without departing from the spirit and scope of the invention.
Example 1
Three Dimensional Structure-Activity Relationship
(3D-QSAR) Models
25

The inventors employed approaches in computer-aided
molecular design (CAMD) to develop 3-dimensional quan
titative structure-activity relationship (3D-QSAR) molecu
lar models based on a series of known opioids for which
experimental binding data are available (Raynor et al.,
1994). These 3D-QSAR models were used as tools to guide
the design of novel, more potent, molecules and to predict
their biological activity prior to the time-consuming chemi
cal synthesis and biological testing of all possible candi
dates. By using 3D-QSAR models to filter or screen out the

30
(FIG. 1). These novel molecules exhibit much improved
bioavailability compared with NTI and SIOM. The bioavail
ability of a pharmaceutical drug relates to the rate and extent
of the active ingredient that reaches the systemic circulation.
To estimate the bioavailability of each compound, the so
called log P that provides a measure of the molecule's
hydrophobic-hydrophilic balance was calculated.
Results from CoMFA and MFA models yielded nearly
identical conclusions, therefore only the CoMFA results are
presented herein. Separate CoMFA models were constructed
for the Ö, K, and L opioids based on published binding data
(Raynor et al., 1994). The results for the 6, K, and L opioids
are summarized in FIG. 2A, FIG. 2B, and FIG. 2C, respec
tively, as plots of the CoMFA-predicted vs. experimentally
observed values of the binding affinity (given as pK). In all
three cases, the 3D-QSAR models exhibited exceptional
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less active candidates, resources can be focused on the most

promising candidates thereby accelerating the drug discov

to these correlation plots served as tools for predicting the
binding affinity of novel molecules.
One of the unique features of CoMFA is its ability to
represent the 3D-QSAR models visually as steric-electro
static pharmacophore maps, as shown in FIG. 3 for the
6-selective opioids. These CoMFA contour maps were used
as visual guides for designing novel 6-selective molecules.
Green-colored polygons denoted regions where increased
steric bulk (i.e., additional chemical groups) is favorable for
enhanced 6 opioid activity, whereas yellow polygons
denoted regions where decreased steric bulk (i.e., fewer
chemical groups) is favorable for enhanced 6 opioid activity.
Likewise, the red polygons denoted regions where negative
electrostatic charge (e.g., from acidic groups) is favorable
while the yellow polygons denoted regions where positive
electrostatic charge (e.g., from basic groups) is favorable for
enhance 8 opioid activity. This information provided infor
mation in designing molecules that exhibited both high
binding affinity and high selectivity for the 8 opioid receptor.

ery process.

Initial structural geometries were obtained from the pub
lished X-ray crystal structures of several opioids included in
this study. Each molecular structure was geometrically opti
mized within the Sybyl molecular modeling program (Tri
pos Inc., St. Louis, Mo.). Separate 3D-QSAR models were
constructed for the three types of opioid receptors (Ö, K, and
u), thus providing a tool for rational design of novel 6-spe
cific candidates. To build these 3D-QSAR models, two
independent techniques were employed: CoMFA (Compara
tive Molecular Field Analysis) (Cramer III et al., 1988),
accessed through the Sybyl program, and MFA (Molecular

Field Analysis) accessed through the Cerius’ program (Mo

lecular Simulations, Inc., San Deigo, Calif.). CoMFA and
MFA are independent yet highly complementary, thus results
from each approach served as an internal check on the
computational methodology.
After establishing the statistical validity, these 3D-QSAR
models were employed as tools to guide the design of novel
molecules and to predict their biological activity prior to
chemical synthesis (thus saving tremendous time and
expense). Based on these 3D-QSAR models, “pharmacoph
oric maps” were constructed that identify those key struc
tural groups responsible for conferring receptor affinity and
selectivity and that visually depict the relative orientation of
these key groups in 3D space. Using this knowledge, a large
number of (>150) of novel 6-selective molecules were
computer-designed representing structural analogues of the
well-known opioids morphine (a L-selective agonist), NTI (a
6-selective antagonist), and SIOM (a 6-selective agonist)

Example 2
40

Design of Novel 8-Selective Opioids: Analogues of
NTI and SIOM

45

50

Using the 3D-QSAR models and pharmacophoric maps,
a large number of novel NTI and SIOM analogs (>100) that
retain or exceed the 8-receptor affinity and selectivity of NTI
and SIOM yet exhibit improved bioavailability, were com
puter-designed. The binding affinities (pK) of these novel
molecules, for all three opioid receptors (Ö, K, and u), were
predicted using the appropriate 3D-QSAR model. The
results for a subset of these novel molecules are summarized

55

60
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in FIG. 4 for the NTI analogues and in FIG. 5 for the SIOM
analogues. Many of these novel compounds are predicted to
exhibit equal or superior binding affinity and selectivity for
the 8 receptor compared with NTI (far left in FIG. 4) and
SIOM (far left in FIG. 5). It should be noted that both NTI
(a ö antagonist) and SIOM (a 6 agonist) possess high binding
affinity and high selectivity for the 8 opioid receptor.
The 8-receptor binding affinity and selectivity of these
NTI and SIOM analogs was either maintained or improved
while significantly improving bioavailability. This is illus
trated in FIG. 6, where the calculated log Pvalues (C log P)
of selected novel compounds are given vs. NTI (log P-3.3).
Preferred NTI and SIOM analogs and their receptor
affinities are shown in Table 3 and Table 4 respectively. The
structures of compounds 1-20 are nonlimiting examples for
the current invention.
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TABLE 3

Newly Designed Opioid Analogs and Their Predicted Activity
Against 8, 1 and K Receptors with Different Models
Predicted Activity
No.

Structure

NTI

8 receptor I receptor K receptor Clog P
10.76

7.19

7.19

(10.70)#

(7.19);

(7.18)#

2.65

10.41

7.96

7.81

3.2

10.94

7.43

7.17

3.6

9.56

8.37

9.01

4.7

OH

2

D

OH

NH
OH

3

D

OH

NH
OH
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TABLE 3-continued
Newly Designed Opioid Analogs and Their Predicted Activity
Against 8, 1 and K Receptors with Different Models
Predicted Activity
No.

Structure

P

8 receptor LL receptor K receptor Clog P
10.23

8-12

8.11

4.7

9.52

8.08

7.36

4.7

9.24

9.18

10.41

4.7

9.57

8.00

6.89

5.3

OH

NH
OH

N
OH

NH
OH

N
OH

O
OH

P
OH

OH
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TABLE 3-continued
Newly Designed Opioid Analogs and Their Predicted Activity
Against 8, 1 and K Receptors with Different Models
Predicted Activity
No.

Structure

8

8 receptor I receptor K receptor Clog P

P

9.45

8.08

6.97

4.7

9.23

6.81

S.26

2.O

7.86

8.15

6.22

2.9

N
OH

N
H
OH

9

s
s
N

OH

O

O

OH

10

N

OH

O

O

OH

# Values in parenthesis are the corresponding experimental affinities of NTI (Naltrindole) against
the three receptors
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TABLE 4

Newly Designed Opioid Analogs and Their Predicted Activities
Against 8, 1 and K Receptors
Predicted Activity
No.

Structure

8 receptor I receptor K receptor Clog P

SIOM

8.74

747

6.02

1.5

11

8.21

6.72

6.40

2.2

12

8.08

6.06

4.64

1.4

8.21

6.64

6.40

1.3

13

H
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TABLE 4-continued
Newly Designed Opioid Analogs and Their Predicted Activities
Against 8, 1 and K Receptors
Predicted Activity
No.

Structure

8 receptor LL receptor K receptor Clog P

14

8.14

6.69

6.44

1.6

15

8.2O

6.63

6.41

1.6

16

8.67

6.82

6.07

1.2

17

9.17

6.57

5.25

1.2
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TABLE 4-continued
Newly Designed Opioid Analogs and Their Predicted Activities
Against 8, 1 and K Receptors
Predicted Activity
No.

Structure

8 receptor I receptor K receptor Clog P

18

19

2O

CH

CH3

CH

CH3

8.49

6.38

6.39

0.7

8.34

6.57

6.26

1.3

8.43

6.44

6.OS

0.4

# Values in parenthesis are the corresponding experimental affinities of SIOM against the three
receptors.
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Use of 3D-QSAR mapping resulted in a pharmacophoric
map of 8-selective compounds of which the structure of
compounds 21–50 are list in Table 5 and compounds 68–70
are listed in Table 6.
TABLE 5

Opioid Analogs and Their Predicted Activities Against 8, 1 and K Receptors
Predicted Activity
No.

Structure

8 receptor LL receptor K receptor Clog P

21

7.83

6.87

6.23

O.24

22

9.95

6.90

6.16

O.94

23

9.29

6.72

6.2O

1.48

8.25

6.41

6.32

1.48

24

t ?
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TABLE 5-continued

Opioid Analogs and Their Predicted Activities Against 8, 1 and K Receptors
Predicted Activity
No.

Structure

8 receptor LL receptor K receptor Clog P

25

8.35

6.90

5.86

1.38

26

1O.S1

7.45

6.92

1.46

27

8.49

7.19

6.95

2.82

28

7.58

6.73

5.87

2.00
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TABLE 5-continued
Opioid Analogs and Their Predicted Activities Against 8, 1 and K Receptors

Predicted Activity
No.

32

Structure

D

8 receptor LL receptor K receptor Clog P
8.52

6.47

6.54

1.28

9.16

6.69

6.06

1.90

10.67

7.49

7.04

2.33

11.65

7.38

7.44

2.91

9.07

8.69

8.O1

2.47

N

33 D
N
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TABLE 5-continued
Opioid Analogs and Their Predicted Activities Against 8, LL and K Receptors

Predicted Activity
No.

Structure

8 receptor LL receptor K receptor Clog P
6.85

7.83

7.32

1.90

11.98

7.38

6.73

3.41

10.94

7.32

7.11

2.24

11:49

8.50

6.91

4.26

11.53

7.09

7.28

2.88.
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TABLE 5-continued

Opioid Analogs and Their Predicted Activities Against 8, 1 and K Receptors
Predicted Activity
No.

40

Structure

D

8 receptor LL receptor K receptor Clog P
11.28

7.20

7.20

2.26

11.10

7.43

6.70

2.29

10.02

7.27

7.23

2.47

10.95

7.30

7.68

1.55

N

41

D
N

42

D
N
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TABLE 5-continued
Opioid Analogs and Their Predicted Activities Against 8, LL and K Receptors

Predicted Activity
No.

Structure

8 receptor LL receptor K receptor Clog P
10.67

8.33

8.54

2.50

1119

7.19

7.82

1.68

10.93

7.49

7.16

1.46

11.21

7.63

7.39

1.49

10.28

8.04

7.72

1.67
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TABLE 5-continued

Opioid Analogs and Their Predicted Activities Against 8, 1 and K Receptors
Predicted Activity
No.

Structure

8 receptor LL receptor K receptor Clog P
10.48

8.75

7.91

O.74

11.10

7.49

7.95

1.70

10.27

8.66

7.94

O.87

TABLE 6
Opioid Analogs and Their Predicted Activities Against 8, LL and K Receptors

Predicted Activity
No.
68

Structure

8 receptor I receptor K receptor Clog P
8.44

7.87

7.72

1.9
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TABLE 6-continued
Opioid Analogs and Their Predicted Activities Against 8, LL and K Receptors

Predicted Activity
No.

Structure

8 receptor LL receptor K receptor Clog P

69

9.66

7.64

7.08

70

10.21

6.16

6.22

2.3

Example 3
Chemical Synthesis
40

(i) Table 1
Compound X

The synthesis of SIOM-based analog, OP-26 is given in
Scheme 4. The synthesis of naltrindole-based analogs (OP
44 derivatives) is provided in Scheme 5.

Lactose
Providone
Croscarmellose sodium
45

Example 4

Microcrystalline cellulose
Magnesium Stearate

Mg/tablet
1OO.O
77.5
1S.O
12.0
92.5
3.0
3OO.OO

Biological Evaluation of Delta Opioid-Receptor
Affinity and Selectivity

(ii) Table 2

In vivo studies using animal models will be carried out on
the compounds of the current invention having high bio
availability. Compounds such as OP-44a and OP-44b which
may have high bioavailability will be subject to testing using 55
rat or other animal models for example as described in U.S.
Pat. No. 5,922,887 and U.S. Pat. No. 6,359,111.
Example 5

Mg/tablet

50

Compound X
Microcrystalline cellulose
Starch

Sodium starch glycolate
Magnesium Stearate
SOO.O

(iii) Capsule

60

Pharmaceutical Dosage Forms
The following illustrate representative pharmaceutical
dosage forms, containing a compound of the invention 65
(“Compound X), such as Formula I or II for therapeutic or
prophylactic use in humans.

Compound X
Colloidal silicon dioxide
Lactose

Pregelatinized starch
Magnesium Stearate

Mg/capsule

US 7,164,021 B2
60
ity (~10/1). One particular feature noted about DST3-2 is
that it exhibits good activity even thought it lacks a basic
nitrogen common to virtually all opioid receptor active
compounds. Currently, the derivative which contains the
basic nitrogen group R3= N(CH3)2 is been synthesized.

-continued
(iv) Injection 1 (1 mg/ml)
Compound X (free acid form)
Dibasic sodium phosphate
Monobasic sodium phosphate
Sodium chloride

1.0 N Sodium hydroxide solution
(pH adjustment to 7.0–7.5)
Water for injection

(v) Injection 2 (10 mg/ml)
Compound X (free acid form)
Monobasic sodium phosphate
Dibasic sodium phosphate
Polyethylene glycol 400
01 N. Sodium hydroxide solution

(pH adjustment to 7.0–7.5)
Water for injection

Mg/ml
1.O
12.0
0.7
4.5

C.S

q. Sad 1 mL.

10

DST3-2
N-N

Mg/ml
1O.O
O.3
1.1
2OO.O
C.S.

R3

-kN \

R1

21

R4

15

NX

q. Sad 1 mL.

R2

(vi) Aerosol
Compound X
Oleic acid

Mg, can
2O.O
1O.O

Trichloromonofluoromethane
Dichlorodifluoromethane
Dichlorotetrafluoroethane

5,000.0
10,000.0
5,000.0

N-N
25

The above formulations may be obtained by conventional
procedures well known in the pharmaceutical art.
Example 6

N

30

DST Analogue (DST3-2)

OH

As demonstrated in Table 7 and FIG. 7, the opoid, DST
analogue (DST3-2) was found to exhibit reasonably high
delta binding affinity (140 nM) and good delta/mu selectiv
TABLE 7

%. Inhibition". Representative K."
R1

R4

R2

R3 MW

8

K

8

phenyl H meta-OH H 313 84 84 42 140 nM
"Competitive analysis; reference compound H-Bremazocine
Dose response curves shown in FIG. 7.
DST3-2

l

1000 nM

All of the methods and compositions disclosed and
50

55

60

claimed herein can be made and executed without undue

experimentation in light of the present disclosure. While the
compositions and methods of this invention have been
described in terms of preferred embodiments, it will be
apparent to those of skill in the art that variations may be
applied to the methods and in the steps or in the sequence of
steps of the method described herein without departing from
the concept, spirit and scope of the invention. More specifi
cally, it will be apparent that certain agents which are both
chemically and physiologically related may be substituted
for the agents described herein while the same or similar
results would be achieved. All such similar substitutes and

65

modifications apparent to those skilled in the art are deemed
to be within the spirit, scope and concept of the invention as
defined by the appended claims.
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-continued
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or wherein R and Ra comprise a ring system selected
from:

35
O

40

45
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R is H or t-butyl; and
Rs is CH methylcyclopropane, a linear alkyl, a branched
alkyl, a substituted alkyl, or a substituted branched
alkyl:
R is H, CH, a linear alkyl, a branched alkyl, a substituted
alkyl, or a substituted branched alkyl; or
a pharmaceutically acceptable salt thereof.
2. The composition of claim 1, wherein
R is O, or NH;
R and R comprise a ring system selected from:
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R and R comprise a ring system selected from:

-continued

OH

R is H:
Rs is methylcyclopropane; or
or a pharmaceutically acceptable salt thereof.
3. The composition of claim 1, wherein
R is O, or NH;
R is =O;

10

65

Rs is methyl; or
a pharmaceutically acceptable salt thereof.
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4. The composition of claim 1, wherein
R is O, or NH;
R is H, or =O:
R is phenoxy;
R is H or t-butyl; and
Rs is CH methylcyclopropane, a linear alkyl, a branched
alkyl, a substituted alkyl, or a substituted branched
alkyl:
or a pharmaceutically acceptable salt thereof.
5. The composition of claim 4, wherein Rs is CH or
methylcyclopropane.
6. The composition of claim 1, wherein
R is O, or NH;
R is H:
Rs is methyl; and
R and R comprise:

68
or a pharmaceutically acceptable salt thereof.
7. The composition of claim 1, wherein
R is O, or NH;
R is =O;
R and R comprise:

10

15

Rs is methylcyclopropyl; or
a pharmaceutically acceptable salt thereof.
8. A pharmaceutical composition comprising a compound
according to claim 1 and a pharmaceutically acceptable
carrier.

9. A pharmaceutical composition comprising a compound
according to claim 7 and a pharmaceutically acceptable
carrier.
25

